Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Completed

Looking for future studies?

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion criteria

None

Treatment and study plan

Anastrozole

Drug

Other names: Arimidex

Primary outcomes

evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions

Time frame: 12 months

Secondary outcomes

description of population treated with anastrozole

Time frame: 12 months
further information about the change of specific laboratory parameters

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis

Acronym: Ax-003

Important dates

Study start: 2005
Study completion: 2007
First posted: Mar 19, 2008
Registry last updated: Mar 20, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed